Challenges of microRNA‐based biomarkers in clinical application for cardiovascular diseases

Gonzalo-Calvo, David de; Pérez-Boza, Jennifer; Curado, João; Devaux, Yvan

doi:10.1002/ctm2.585

Cited by 27 publications

(21 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before miRNA expression can be used in routine patient management, some challenges need to be overcome. These challenges are detailed in recent reviews 75,82 and range from standardization of the specimen type, pre-analytical issues like specimen processing and storage, to data analysis and interpretation. The choice of the specimen type, including the blood fraction (plasma or serum) and anticoagulant (EDTA, heparin or citrate) influence both miRNA levels.…”

Section: Future Perspectives and Challengesmentioning

confidence: 99%

“…As far as analytical procedures are concerned, different RNA isolation protocols may impact the efficacy of small RNA isolation. 75,82 Furthermore the technique chosen for miRNA quantification can impact on the results. 82 The importance of controls used for monitoring of RNA extraction quality cannot be underestimated.…”

Section: Future Perspectives and Challengesmentioning

confidence: 99%

“…75,82 Furthermore the technique chosen for miRNA quantification can impact on the results. 82 The importance of controls used for monitoring of RNA extraction quality cannot be underestimated. Finally, the methods of normalization and statistical analyses also influence the results and should be critically reviewed.…”

Section: Future Perspectives and Challengesmentioning

confidence: 99%

See 2 more Smart Citations

Host miRNAs as biomarkers of SARS-CoV-2 infection: a critical review

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Future Perspectives and Challengesmentioning

confidence: 99%

Section: Future Perspectives and Challengesmentioning

confidence: 99%

See 1 more Smart Citation

Host miRNAs as biomarkers of SARS-CoV-2 infection: a critical review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The long-term clinical use of miRNAs necessitates additional work to address current methodological, technical, or analytical shortcomings. Standard operating protocols, coordinated miRNA isolation, and quantification techniques are necessary to increase repeatability among different investigations [ 60 ].…”

Section: Gene and Protein Markersmentioning

confidence: 99%

New Progress in Early Diagnosis of Atherosclerosis

Meng

Ruan

Yan

et al. 2022

IJMS

View full text Add to dashboard Cite

Coronary atherosclerosis is a potentially chronic circulatory condition that endangers human health. The biological cause underpinning cardiovascular disease is coronary atherosclerosis, and acute cardiovascular events can develop due to thrombosis, platelet aggregation, and unstable atherosclerotic plaque rupture. Coronary atherosclerosis is progressive, and three specific changes appear, with fat spots and stripes, atherosclerosis and thin-walled fiber atherosclerosis, and then complex changes in arteries. The progression and severity of cardiovascular disease are correlated with various levels of calcium accumulation in the coronary artery. The therapy and diagnosis of coronary atherosclerosis benefit from the initial assessment of the size and degree of calcification. This article will discuss the new progress in the early diagnosis of coronary atherosclerosis in terms of three aspects: imaging, gene and protein markers, and trace elements. This study intends to present the latest methods for diagnosing patients with early atherosclerosis through a literature review.

show abstract

“…Another class of molecules, microRNAs (miRNAs), have been described as potential biomarkers for various diseases such as cancer, auto-immune diseases, and more recently CVD [ 9 ]. The use of miRNAs as prognostic markers for post-acute myocardial infarction (AMI) evolution is still under evaluation and clinical validation [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Mitochondrial DNA Together with miR-142-3p in Plasma Can Predict Unfavorable Outcomes in Patients after Acute Myocardial Infarction

Barbalata

Scărlătescu

Sanda

et al. 2022

IJMS

View full text Add to dashboard Cite

Myocardial infarction is one of the leading causes of death worldwide, despite numerous efforts to find efficient prognostic biomarkers and treatment targets. In the present study, we aimed to assess the potential of six microRNAs known to be involved in cardiovascular diseases, cell-free DNA (cfDNA), and mitochondrial DNA (mtDNA) circulating in plasma to be used as prognostic tools for the occurrence of unfavorable outcomes such as major adverse cardiovascular events (MACE) after acute ST-segment elevation myocardial infarction (STEMI). Fifty STEMI patients were enrolled and monitored for 6 months for the occurrence of MACE. Plasma was collected at three time points: upon admission to hospital (T0), at discharge from hospital (T1), and 6 months post-STEMI (T6). Plasma levels of miR-223-3p, miR-142-3p, miR-155-5p, miR-486-5p, miR-125a-5p, and miR-146a-5p, as well as of cfDNA and mtDNA, were measured by RT-qPCR. Results showed that the levels of all measured miRNAs, as well as of cfDNA and mtDNA, were the most increased at T1, compared to the other two time points. In the plasma of STEMI patients with MACE compared to those without MACE, we determined increased levels of miRNAs, cfDNA, and mtDNA at T1. Hence, we used the levels of all measured parameters at T1 for further statistical analysis. Statistical analysis demonstrated that all six miRNAs and cfDNA plus mtDNA levels, respectively, were associated with MACE. The minimal statistical model that could predict MACE in STEMI patients was the combination of mtDNA and miR-142-3p levels, as evidenced by ROC analysis (AUC = 0.97, p < 0.001). In conclusion, the increased plasma levels of mtDNA, along with miR-142-3p, could be used to predict unfavorable outcomes in STEMI patients.

show abstract

Challenges of microRNA‐based biomarkers in clinical application for cardiovascular diseases

Cited by 27 publications

References 11 publications

Host miRNAs as biomarkers of SARS-CoV-2 infection: a critical review

Host miRNAs as biomarkers of SARS-CoV-2 infection: a critical review

New Progress in Early Diagnosis of Atherosclerosis

Mitochondrial DNA Together with miR-142-3p in Plasma Can Predict Unfavorable Outcomes in Patients after Acute Myocardial Infarction

Contact Info

Product

Resources

About